Virtu Financial’s BioNexus Gene Lab BGLC Stock Holding History

Virtu Financial’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,737	Closed	-$13K	–	1380
2024 Q2	$13K	Sell	2,737 -1,967	-42%	-$11K	﹤0.01%	1093
2024 Q1	$33K	Buy	4,704 +2,089	+80%	+$13.7K	﹤0.01%	1087
2023 Q4	$14K	Sell	2,615 -3,354	-56%	-$19.1K	﹤0.01%	1371
2023 Q3	$50K	Buy	+5,969	New	+$97.2K	0.01%	902

Other funds holding BGLC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Virtu Financial's BGLC Position: Q3 2024 in Review

Virtu Financial sold out of BioNexus Gene Lab (BGLC) in Q3 2024, closing a stake of 2,737 shares — an estimated $13K sold.

Virtu Financial first reported a position in BGLC in Q3 2023 and held it in 4 quarters. The position peaked at $50K in Q3 2023. 4 funds tracked by Wall St. Rank hold BGLC as of Q3 2024.

Virtu Financial reported no remaining BioNexus Gene Lab position as of Q3 2024 after selling out during the quarter.
Virtu Financial sold 2,737 BioNexus Gene Lab shares in Q3 2024, an estimated $13K.
Virtu Financial first reported a position in BioNexus Gene Lab in Q3 2023 and held it in 4 quarters.
Virtu Financial's BioNexus Gene Lab position peaked at $50K in Q3 2023.
4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.